Clopidogrel Proton-Pump Inhibitors Study
Overview[ - collapse ][ - ]
| Purpose | To find out the impact of two different proton-pump inhibitors (PPIs) (Omeprazole and Pantoprazole) on platelet function in patients with stable coronary artery disease (CAD) on clopidogrel therapy. |
|---|---|
| Condition | Coronary Artery Disease |
| Intervention | Drug: Omeprazole Drug: Pantoprazole |
| Phase | Phase 4 |
| Sponsor | Sheba Medical Center |
| Responsible Party | Sheba Medical Center |
| ClinicalTrials.gov Identifier | NCT01016717 |
| First Received | November 18, 2009 |
| Last Updated | June 14, 2012 |
| Last verified | June 2012 |
Tracking Information[ + expand ][ + ]
| First Received Date | November 18, 2009 |
|---|---|
| Last Updated Date | June 14, 2012 |
| Start Date | December 2012 |
| Estimated Primary Completion Date | December 2013 |
| Current Primary Outcome Measures | Platelet function tests. [Time Frame: 30 days] [Designated as safety issue: No] |
| Current Secondary Outcome Measures | Not Provided |
Descriptive Information[ + expand ][ + ]
| Brief Title | Clopidogrel Proton-Pump Inhibitors Study |
|---|---|
| Official Title | Clopidogrel Proton-Pump Inhibitors Study |
| Brief Summary | To find out the impact of two different proton-pump inhibitors (PPIs) (Omeprazole and Pantoprazole) on platelet function in patients with stable coronary artery disease (CAD) on clopidogrel therapy. |
| Detailed Description | On June 19, 2009 The European Medicines Agency (EMEA) has issued a public statement on a possible interaction between clopidogrel (Plavix, Sanofi-Aventis/Bristol-Myers Squibb)and proton-pump inhibitors (PPIs) and has recommended that the product information for all clopidogrel-containing medicines be amended to discourage concomitant use of PPIs unless absolutely necessary. The UK medicines regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), has also issued advice to GPs that concomitant use of a PPI with clopidogrel is not recommended unless considered essential, urging a review of the prescribing of PPIs at the next appointment for patients taking clopidogrel. This follows an "early communication" issued by the US FDA earlier this year, stating that PPIs might interfere with the effectiveness of clopidogrel and that clinicians should reevaluate starting or continuing treatment with a PPI in patients taking clopidogrel. There is a concern that the studies on which these warnings are based have many limitations and that it is far from certain whether there really is an interaction between clopidogrel and PPIs. Another point of uncertainty is whether there may be a difference between individual PPIs, with some pharmacodynamic studies suggesting an interaction with omeprazole but not with pantoprazole. The clinical evidence, however, is conflicting. There has been one clinical trial from Canada suggesting an interaction with omeprazole but not with pantoprazole. From a mechanistic view it is known that omeprazole is metabolized by the CYP219 enzyme, which converts clopidogrel into its active metabolite. And while pantoprazole can also be metabolized by this enzyme, it also uses other routes. Thus, the primary goal of the current study is to find out the impact of two different PPIs (Omeprazole, Losec, and Pantoprazole) on platelet function in patients with stable coronary artery disease (CAD) on clopidogrel therapy. Forty patients with stable CAD will be randomized to receive either omeprazole tables (Losec, 40 mg/day, Abic Inc., Israel) or pantoprazole tables (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel) for 1 month (Phase 1), followed by a 4-week washout period, and the alternative treatment for 1 month (Phase 2).Platelet function tests will be assessed 4 times: before and after each study phase. Following an overnight fast, ECG and blood tests for measurements of platelet function, lipids, blood cell count, electrolytes, fasting glucose, and high-sensitivity C-reactive protein (hs-CRP), will be performed. The blood samples, except those for platelet function, will be centrifuged immediately for 15 minutes at 3000/min. The sera will be stored at -20° C, and will be tested at the end of the study. Blood samples for platelet function will be assessed immediately after the blood is drawn. All blood samples will be evaluated in the same laboratory and by the same operator who will be blinded to the patients' clinical status and PPIs allocation. All patients will be instructed to continue taking their regular medications throughout the study period. In addition, patients will be instructed not to add any medications (including over the counter medications) and to record any change in concomitant medications throughout the study period. |
| Study Type | Interventional |
| Study Phase | Phase 4 |
| Study Design | Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment |
| Condition | Coronary Artery Disease |
| Intervention | Drug: Omeprazole All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days Other Names: LosecDrug: Pantoprazole Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days Other Names: Controloc |
| Study Arm (s) |
|
Recruitment Information[ + expand ][ + ]
| Recruitment Status | Suspended |
|---|---|
| Estimated Enrollment | 40 |
| Estimated Completion Date | December 2013 |
| Estimated Primary Completion Date | December 2012 |
| Eligibility Criteria | Inclusion criteria: 1. Male or female ≥ 18 years; signed informed consent 2. Outpatient CAD patients on aspirin tablets 100-325 mg daily and clopidogrel tablets 75 mg daily. 3. Left ventricular (LV) systolic dysfunction ≥ 40% measured within the past 6 months. 4. No changes in cardiac medications during 2 weeks prior to enrollment. Exclusion criteria: 1. Presence of transplanted tissue or organ or LVAD 2. AICD or CRT or CRTD patients. 3. Acute MI, CABG, PCI within past 3 months. 4. Congestive heart failure (CHF) ≥ NYHA 2. 5. Ejection fraction < 40% measured within the past 6 months. 6. Malignancy. 7. Active myocarditis, or cardiomyopathy. 8. HIV infection or immunodeficiency state. 9. Chronic viral infection. 10. Acute systemic infection requiring antibiotics. 11. Chronic diarrhea or malabsorption. 12. Statin therapy initiation ≤ 3 months. 13. Diabetes mellitus type 1. 14. Diabetes mellitus type 2 with HbA1C > 7% 15. Low-density lipoprotein cholesterol (LDL-C) > 100 mg/dL. 16. Not on statin therapy. 17. Liver function tests (LFT) ≥ x 3 upper limit of normal (ULN) or creatinine kinase (CPK) ≥ x 10 ULN. 18. Hypo/hyper thyroidism. 19. Liver dysfunction. 20. Renal failure with serum creatinine ≥ 2 mg/dL. 21. Alcohol or drug abuse. 22. Refuse to sign informed consent. 23. On the following therapy: Amiodarone, coumadin, any antibiotics. |
| Gender | Both |
| Ages | 18 Years |
| Accepts Healthy Volunteers | No |
| Contacts | Not Provided |
| Location Countries | Israel |
Administrative Information[ + expand ][ + ]
| NCT Number | NCT01016717 |
|---|---|
| Other Study ID Numbers | SHEBA-09-7345-MS-CTIL |
| Has Data Monitoring Committee | No |
| Information Provided By | Sheba Medical Center |
| Study Sponsor | Sheba Medical Center |
| Collaborators | Not Provided |
| Investigators | Principal Investigator: Michael Shechter, MD, MA Leviev Heart Center, Sheba Medical Center, Tel Hashomer |
| Verification Date | June 2012 |
Locations[ + expand ][ + ]
| Leviev Heart Center, Sheba Medical Center | Tel Hashomer, Israel, 52621 |
|---|